MX2017016368A - Farmaceuticos para tratamiento de infecciones virales de los ojos. - Google Patents

Farmaceuticos para tratamiento de infecciones virales de los ojos.

Info

Publication number
MX2017016368A
MX2017016368A MX2017016368A MX2017016368A MX2017016368A MX 2017016368 A MX2017016368 A MX 2017016368A MX 2017016368 A MX2017016368 A MX 2017016368A MX 2017016368 A MX2017016368 A MX 2017016368A MX 2017016368 A MX2017016368 A MX 2017016368A
Authority
MX
Mexico
Prior art keywords
viral infections
eye
pharmaceuticals
treatment
vehicle
Prior art date
Application number
MX2017016368A
Other languages
English (en)
Inventor
Squiquera Luis
Sulley Jamie
Original Assignee
Tamir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tamir Biotechnology Inc filed Critical Tamir Biotechnology Inc
Publication of MX2017016368A publication Critical patent/MX2017016368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las infecciones virales de los ojos, y particularmente infecciones virales en las familias Herpesviridae y Adenoviridae, pueden tratarse por la administración de un farmacéutico hecho de una ribonucleasa enzimáticamente activa y un vehículo. Ventajosamente, la ribonucleasa enzimáticamente activa es ranpirnasa, y el vehículo es una solución acuosa.
MX2017016368A 2015-06-15 2016-06-13 Farmaceuticos para tratamiento de infecciones virales de los ojos. MX2017016368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175961P 2015-06-15 2015-06-15
PCT/US2016/037174 WO2016205109A1 (en) 2015-06-15 2016-06-13 Pharmaceuticals for treatment of viral infections of the eye

Publications (1)

Publication Number Publication Date
MX2017016368A true MX2017016368A (es) 2018-04-24

Family

ID=56194615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016368A MX2017016368A (es) 2015-06-15 2016-06-13 Farmaceuticos para tratamiento de infecciones virales de los ojos.

Country Status (12)

Country Link
US (2) US10293032B2 (es)
EP (1) EP3307238A1 (es)
JP (1) JP6862366B2 (es)
KR (1) KR20180026455A (es)
CN (2) CN107920990A (es)
AU (2) AU2016277827B2 (es)
CA (1) CA2989611C (es)
IL (1) IL256327B (es)
MX (1) MX2017016368A (es)
RU (1) RU2739392C2 (es)
SG (1) SG10201911292SA (es)
WO (1) WO2016205109A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US10293032B2 (en) 2015-06-15 2019-05-21 Tamir Biotechnology, Inc. Methods and pharmaceuticals for treatment of viral infections of the eye
WO2017053923A1 (en) * 2015-09-25 2017-03-30 Okogen, Llc Viral conjunctivitis treatment using ranpirnase and/or amphinase
EP3989974A4 (en) * 2019-06-25 2023-07-19 Microbiotix, Inc. COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OCULAR INFECTIONS WITH FILOCICLOVIR
WO2021188866A1 (en) * 2020-03-20 2021-09-23 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021216909A1 (en) * 2020-04-23 2021-10-28 Okogen, Inc. Treatment of viral conjunctivitis

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882421A (en) 1982-09-23 1989-11-21 Alfacell Corporation Pharmaceutical for treating tumors and method for making it
US5728805A (en) 1988-04-06 1998-03-17 Alfacell Corp. Pharmaceuticals and method for making them
US5559212A (en) 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
IL100881A (en) 1992-02-06 1996-06-18 Porat Michael Causal drug prevents diseases, devices and methods of using it
NZ331298A (en) 1996-02-21 2000-03-27 Us Gov Health & Human Serv Recombinant (humanised) ribonuclease proteins derived from a native ribonuclease found in the oocytes of Rana pipiens and uses therefor
US6649392B1 (en) 1996-04-04 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods
US6239257B1 (en) 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
US20030099629A1 (en) 1999-03-11 2003-05-29 Immunomedics, Inc. Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
US6175003B1 (en) 1999-09-10 2001-01-16 Alfacell Corporation Nucleic acids encoding ribonucleases and methods of making them
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20040126865A1 (en) 2002-12-30 2004-07-01 Alfacell Corporation Nucleic acids encoding ranpirnase variants and methods of making them
US7229824B2 (en) 2003-07-17 2007-06-12 Alfacell Corporation Ribonucleases and methods of making them recombinantly
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
EP1720996A4 (en) 2004-02-13 2007-03-21 Immunomedics Inc RECOMBINANT CYTOTOXIC RASES CONTAINING FUSION PROTEINS
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2009088992A2 (en) 2008-01-07 2009-07-16 University Of Vermont And State Agricultural College Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
AU2009320287B2 (en) 2008-11-26 2015-10-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use
CA2782441A1 (en) 2009-12-01 2011-06-09 Seprox Biotech, S.L. Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
US8518399B2 (en) 2010-11-17 2013-08-27 Tamir Biotechnology, Inc. Methods of treating infections originating from viruses in the herpesviridae family
US8663964B2 (en) 2011-07-20 2014-03-04 Tamir Biotechnology, Inc. Methods of treating human papillomavirus
WO2013039857A1 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2790722B1 (en) * 2011-12-12 2018-12-05 The Board of Trustees of the University of Illionis Composition and method for treating nucleic acid-related eye disease
US20170157219A1 (en) 2014-03-28 2017-06-08 Tamir Biotechnology, Inc. Methods of treating zika virus, mers-cov, chikungunya, venezuelan equine encephalitus, and rhinovirus in mammalian patients
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
WO2015148768A2 (en) 2014-03-28 2015-10-01 Tamir Biotechnology, Inc. Rnase for use in treating or preventing viral infections
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US9642794B2 (en) 2014-08-18 2017-05-09 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
US20160045574A1 (en) 2014-08-18 2016-02-18 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
US10293032B2 (en) 2015-06-15 2019-05-21 Tamir Biotechnology, Inc. Methods and pharmaceuticals for treatment of viral infections of the eye
WO2017142807A1 (en) 2016-02-16 2017-08-24 Tamir Biotechnology, Inc. Treatment or prevention of zika virus infections by administration of a ribonuclease

Also Published As

Publication number Publication date
RU2018101139A (ru) 2019-07-15
WO2016205109A1 (en) 2016-12-22
JP2018517423A (ja) 2018-07-05
AU2016277827B2 (en) 2021-04-29
AU2016277827A1 (en) 2018-02-01
RU2739392C2 (ru) 2020-12-23
KR20180026455A (ko) 2018-03-12
IL256327A (en) 2018-02-28
EP3307238A1 (en) 2018-04-18
JP6862366B2 (ja) 2021-04-21
CA2989611A1 (en) 2016-12-22
US10293032B2 (en) 2019-05-21
CA2989611C (en) 2024-02-27
AU2021204520A1 (en) 2021-07-29
IL256327B (en) 2020-01-30
US20190216904A1 (en) 2019-07-18
CN117159694A (zh) 2023-12-05
US20160361392A1 (en) 2016-12-15
CN107920990A (zh) 2018-04-17
SG10201911292SA (en) 2020-02-27
RU2018101139A3 (es) 2019-12-06
AU2021204520B2 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
MX2017016368A (es) Farmaceuticos para tratamiento de infecciones virales de los ojos.
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
BR112016025792A2 (pt) meios e processos para tratamento de cmv
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
SG10201902074UA (en) Heterocyclic compounds and uses thereof
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
BR112018069974A2 (pt) compostos de tiazolida para o tratamento de infecções virais
WO2015058664A8 (zh) 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途
MX2019002781A (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral.
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
PH12017502386A1 (en) Methods of purification and/or viral inactivation
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2016012536A (es) Rnasa para su uso en el tratamiento o la prevencion de infecciones virales.
EP3331356A4 (en) PROGRANULIN (PGRN) FRAGMENTS AND DERIVATIVES FOR THE TREATMENT OR AID OF LYSOSOMAL STORAGE DISEASES
MX2017001461A (es) Terapia de combinacion.
PH12018501624A1 (en) A composition comprising pic for treatment of cancer
BR112018005268A2 (pt) nanopartículas não vesiculares altamente estáveis e aplicação das mesmas no tratamento de infecção microbiana”
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
MX2018012952A (es) Composicion oftalmica que comprende una combinacion sinergica de glucogeno y acido hialuronico o sal del mismo.
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
PH12017500173A1 (en) Post-harvest disease control agent and post-harvest disease control method
MX2016016018A (es) Uso de la terfenadina para el tratamiento de la enfermedad de chagas como agente anti-trypanosoma cruzi.
MX2017001766A (es) Uso de la cefsulodina de sodio para el tratamiento de la enfermedad de chagas como angente anti-trypanosoma cruzi.